Medicure to Present at RBC Healthcare Conference
December 10 2007 - 8:00AM
Marketwired
WINNIPEG, MANITOBA (AMEX: MCU), a cardiovascular focused
biopharmaceutical company, today announced its President and CEO,
Albert D. Friesen, PhD, will participate on the "Replacing The
Mainstay With Newer And Better Agents" panel at the 2007 RBC
Capital Markets Healthcare Conference in New York. The panel
discussion is scheduled for Wednesday, December 12th at 4:30 p.m.
Eastern.
A live audio webcast of the presentation will be accessible
through Medicure's Investor Relations website at www.medicure.com.
An archived edition of the presentation will be available later
that day.
About Medicure Inc.
Medicure is a biopharmaceutical company focused on the research,
development and commercialization of novel compounds to treat
cardiovascular disorders. The Company's solid position in this
field is highlighted by the following:
- Lead compound MC-1 in pivotal Phase 3 study for FDA
approval
- Four positive Phase 2 trials completed with MC-1
- FDA Fast Track designation for MC-1
- U.S. rights to AGGRASTAT� Injection (tirofiban
hydrochloride)
- Combination of MC-1 and lisinopril (MC-4232) completed Phase
2
- Dual action antithrombotic, MC-45308, with positive
preclinical results
Medicure also has a medicinal chemistry based Drug Discovery
program focused on discovery and advancement of novel small
molecule anti-ischemics and antithrombotics towards human clinical
studies.
This press release contains forward-looking statements, as
defined under applicable securities legislation, that involve
risks, which may cause actual results to differ materially from the
statements made, and accordingly may be deemed to be
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements are made as of the date hereof, and
the Company disclaims any intention and has no obligation or
responsibility to update or revise any forward-looking statements,
whether as a result of new information, future events, or otherwise
except as required by law. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements. Such factors
include, among others, the Company's stage of development, lack of
product revenues, additional capital requirements, risks associated
with the completion of clinical trials and obtaining regulatory
approval to market the Company's products, the ability to protect
its intellectual property, dependence on collaborative partners and
the ability to meet its debt obligations. These factors should be
considered carefully and readers are cautioned not to place undue
reliance on such forward-looking statements. Additional risks and
uncertainties relating to the Company and its business can be found
in the "Risk Factors" section of its Form 20F for the year ended
May 31, 2007.
Contacts: Medicure Inc. Derek Reimer Chief Financial Officer
1-888-435-2220 Medicure Inc. Adam Peeler Manager of Investor &
Public Relations 1-888-435-2220 (204) 488-9823 (FAX) Email:
info@medicure.com Website: www.medicure.com
Medicure (AMEX:MCU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medicure (AMEX:MCU)
Historical Stock Chart
From Jul 2023 to Jul 2024